|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2009-7-6
|
|
pubmed:abstractText |
The cancer-testis antigen NY-ESO-1 has been targeted as a tumor-associated antigen by immunotherapeutical strategies, such as cancer vaccines. The prerequisite for a T-cell-based therapy is the induction of T cells capable of recognizing the NY-ESO-1-expressing tumor cells. In this study, we generated human T lymphocytes directed against the immunodominant NY-ESO-1(157-165) epitope known to be naturally presented with HLA-A*0201. We succeeded to isolate autorestricted and allorestricted T lymphocytes with low, intermediate or high avidity TCRs against the NY-ESO-1 peptide. The avidity of the established CTL populations correlated with their capacity of lysing HLA-A2-positive, NY-ESO-1-expressing tumor cell lines derived from different origins, e.g. melanoma and myeloma. The allorestricted NY-ESO-1-specific T lymphocytes displayed TCRs with the highest avidity and best anti-tumor recognition activity. TCRs derived from allorestricted, NY-ESO-1-specific T cells may be useful reagents for redirecting primary T cells by TCR gene transfer and, therefore, may facilitate the development of adoptive transfer regimens based on TCR-transduced T cells for the treatment of NY-ESO-1-expressing hematological malignancies and solid tumors.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Neoplasm,
http://linkedlifedata.com/resource/pubmed/chemical/CTAG1B protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/HLA-A*02:01 antigen,
http://linkedlifedata.com/resource/pubmed/chemical/HLA-A Antigens,
http://linkedlifedata.com/resource/pubmed/chemical/HLA-A2 Antigen,
http://linkedlifedata.com/resource/pubmed/chemical/Membrane Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Neoplasm Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Peptide Fragments,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Antigen, T-Cell,
http://linkedlifedata.com/resource/pubmed/chemical/peptide NY-ESO-1 157-165
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
1097-0215
|
|
pubmed:author |
pubmed-author:BernhardHelgaH,
pubmed-author:BuschDirk HDH,
pubmed-author:ConradHeinkeH,
pubmed-author:CosmaAntonioA,
pubmed-author:GuilaumePhilippeP,
pubmed-author:HoferKathrinK,
pubmed-author:KrönigHolgerH,
pubmed-author:LennerzVolkerV,
pubmed-author:MüllerJuliaJ,
pubmed-author:PeschelChristianC,
pubmed-author:RomeroPedroP,
pubmed-author:SchiemannMatthiasM
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
1
|
|
pubmed:volume |
125
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
649-55
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:19444908-Antibody-Dependent Cell Cytotoxicity,
pubmed-meshheading:19444908-Antigen Presentation,
pubmed-meshheading:19444908-Antigens, Neoplasm,
pubmed-meshheading:19444908-Cytotoxicity Tests, Immunologic,
pubmed-meshheading:19444908-Enzyme-Linked Immunosorbent Assay,
pubmed-meshheading:19444908-Flow Cytometry,
pubmed-meshheading:19444908-Genes, T-Cell Receptor,
pubmed-meshheading:19444908-HLA-A Antigens,
pubmed-meshheading:19444908-HLA-A2 Antigen,
pubmed-meshheading:19444908-Humans,
pubmed-meshheading:19444908-Membrane Proteins,
pubmed-meshheading:19444908-Neoplasm Proteins,
pubmed-meshheading:19444908-Peptide Fragments,
pubmed-meshheading:19444908-Protein Multimerization,
pubmed-meshheading:19444908-Receptors, Antigen, T-Cell,
pubmed-meshheading:19444908-T-Lymphocytes, Cytotoxic
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Allorestricted T lymphocytes with a high avidity T-cell receptor towards NY-ESO-1 have potent anti-tumor activity.
|
|
pubmed:affiliation |
Department of Hematology/Oncology, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|
